Abstract
Objective Primary ciliary dyskinesia (PCD) is a rare congenital motile ciliopathy associated with significant sinopulmonary disease, alongside marked genetic and phenotypic variability. Olfactory dysfunction in PCD remains poorly characterised. This systematic review aimed to synthesise the available evidence on the prevalence, assessment methods, and clinical correlates of olfactory dysfunction in individuals with PCD.
Methods A PRISMA-compliant systematic review was conducted. Medline, Embase, Scopus, Web of Science, and the Cochrane Library were searched up to 28/02/26. Observational studies and clinical trials reporting on olfactory function in confirmed PCD were included. Data were extracted, and study quality was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects meta-analysis using the Freeman-Tukey double arcsine transformation was performed to calculate the pooled prevalence, 95% confidence interval (CI), and 95% prediction interval (PI). The review protocol was registered with PROSPERO (CRID: 1006332).
Results Of 159 records screened, 12 studies (n=865) met the inclusion criteria. The prevalence of olfactory dysfunction varied widely, from 1.5% to 100%. The overall pooled prevalence was 43.4% (95% CI 25.2%–62.5%), but with a very wide 95% prediction interval of 0.1%–99.0%, reflecting significant heterogeneity (I²=96.2%). Objective psychophysical tests (n=6 studies) identified a pooled prevalence of 66.1% (95% CI 55.5%–76.0%; 95% PI 38.4%–88.9%), which was significantly higher than that from patient-reported outcome measures (30.5%; 95% CI 11.4%–54.0%; 95% PI 11.4%–97.1%) and clinical history (5.6%; 95% CI 0.2%–24.8%). Older age, specific ciliary ultrastructural defects, and greater sinonasal disease burden on imaging were associated with worse olfactory function.
Conclusion Olfactory dysfunction is a highly prevalent yet profoundly under-recognised comorbidity in Primary Ciliary Dyskinesia, with over two-thirds of patients affected when assessed objectively. The pathophysiology extends beyond simple conductive obstruction to likely include a primary neurosensory deficit linked to the underlying genetic defect. These findings carry a clear mandate for clinicians to integrate objective olfactory testing into routine PCD care to improve patient safety and quality of life.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251006332.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint senior author
This paper has been presented as a poster presentation at the Annual Conference of British Association of Paediatric Otolaryngology(BAPO) held in September 2025.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
